Noninvasive serum models to predict significant liver related events in chronic hepatitis C. (Q40151847)

18 September 2017

title

Noninvasive serum models to predict significant liver related events in chronic hepatitis C. (English)

1 reference

18 September 2017

author name string

Ragesh Babu Thandassery

1

1 reference

18 September 2017

Saad Al Kaabi

2

1 reference

18 September 2017

Madiha E Soofi

3

1 reference

18 September 2017

Benjamin Tharian

4

1 reference

18 September 2017

Rajvir Singh

5

1 reference

18 September 2017

publication date

20 June 2017

1 reference

18 September 2017

published in

Hepatology international

1 reference

18 September 2017

volume

11

1 reference

18 September 2017

issue

4

1 reference

18 September 2017

page(s)

401-408

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Grazoprevir + elbasvir for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

21 January 2018

Direct anti-HCV agents

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Classification of chronic viral hepatitis: a need for reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Mean Platelet Volume, Red Cell Distribution Width to Platelet Count Ratio, Globulin Platelet Index, and 16 Other Indirect Noninvasive Fibrosis Scores: How Much Do Routine Blood Tests Tell About Liver Fibrosis in Chronic Hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Serum models accurately predict liver-related clinical outcomes in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-017-9800-7

Prognostic value of liver fibrosis biomarkers: a meta-analysis.

21 January 2018

1 reference

12 December 2020

Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol

1 reference

12 December 2020

Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

1 reference

12 December 2020

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

1 reference

12 December 2020

10.1007/S12072-017-9800-7

Identifiers

DOI

1 reference

18 September 2017

1 reference